Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TTH006
MIFTS: 47

Tooth Disease

Categories: Oral diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Tooth Disease

About this section

MalaCards integrated aliases for Tooth Disease:

Name: Tooth Disease 11 14 16
Tooth Diseases 43 71
Tooth Disorders 41
Teeth Disease 11

Classifications:

MalaCards categories:
Anatomical: Oral diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:1091
MeSH 43 D014076
SNOMED-CT 68 367503003
UMLS 71 C0040435
Sources

Summaries for Tooth Disease

About this section

MedlinePlus: 41 What are teeth? Your teeth are made of a hard, bonelike material. There are four parts: Enamel, your tooth's hard surface Dentin, the hard yellow part under the enamel Cementum, the hard tissue that covers the root and keeps your teeth in place Pulp, the soft connective tissue in the center of your tooth. It contains nerves and blood vessels. You need your teeth for many activities that you may take for granted. These include eating, speaking and even smiling. What are tooth disorders? There are many different problems that can affect your teeth, including: Tooth decay - damage to a tooth's surface, which can lead to cavities Abscess - a pocket of pus, caused by a tooth infection Impacted tooth - a tooth did not erupt (break through the gum) when it should have. It is usually wisdom teeth that are impacted, but it can sometimes happen to other teeth. Misaligned teeth (malocclusion) Tooth injuries such as broken or chipped teeth What causes tooth disorders? The causes of tooth disorders varies, depending on the problem. Sometimes the cause is not taking good care of your teeth. In other cases, you may have been born with the problem or the cause is an accident. What are the symptoms of tooth disorders? The symptoms can vary, depending on the problem. Some of the more common symptoms include: Abnormal color or shape of the tooth Tooth pain Worn-down teeth How are tooth disorders diagnosed? Your dentist will ask about your symptoms, look at your teeth, and probe them with dental instruments. In some cases, you may need dental x-rays. What are the treatments for tooth disorders? The treatment will depend on the problem. Some common treatments are: Fillings for cavities Root canals for cavities or infections that affect the pulp (inside of the tooth) Extractions (pulling teeth) for teeth that are impacted and causing problems or are too damaged to be fixed. You may also have a tooth or teeth pulled because of overcrowding in your mouth. Can tooth disorders be prevented? The main thing that you can do to prevent tooth disorders is to take good care of your teeth: Brush your teeth twice a day with a fluoride toothpaste Clean between your teeth every day with floss or another type of between-the-teeth cleaner Limit sugary snacks and drinks Don't smoke or chew tobacco See your dentist or oral health professional regularly

MalaCards based summary: Tooth Disease, also known as tooth diseases, is related to charcot-marie-tooth disease, axonal, type 2p and charcot-marie-tooth disease, axonal, type 2n, and has symptoms including snoring, halitosis and toothache. An important gene associated with Tooth Disease is GJB1 (Gap Junction Protein Beta 1), and among its related pathways/superpathways are Neural crest differentiation and Intracellular trafficking proteins involved in CMT neuropathy. The drugs Ketamine and Folic acid have been mentioned in the context of this disorder. Affiliated tissues include teeth, spinal cord and bone, and related phenotypes are Increased gamma-H2AX phosphorylation and nervous system

Disease Ontology: 11 A mouth disease located in the teeth.
Sources

Related Diseases for Tooth Disease

About this section

Diseases related to Tooth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 642)
# Related Disease Score Top Affiliating Genes
1 charcot-marie-tooth disease, axonal, type 2p 33.2 SH3TC2 MPZ LRSAM1 LITAF GDAP1
2 charcot-marie-tooth disease, axonal, type 2n 33.2 MPZ MFN2 KIF1B GDAP1
3 charcot-marie-tooth disease, x-linked recessive, 5 33.2 SH3TC2 PRPS1 GJB1
4 charcot-marie-tooth disease, axonal, type 2b1 33.2 LMNA GDAP1
5 charcot-marie-tooth disease, dominant intermediate c 33.1 MPZ GJB1 GDAP1
6 charcot-marie-tooth disease, axonal, type 2d 33.1 SH3TC2 NEFL MPZ MFN2 HSPB8 GJB1
7 charcot-marie-tooth disease, axonal, type 2a1 33.1 MPZ MFN2 LRSAM1 KIF1B HSPB8 GDAP1
8 charcot-marie-tooth disease, recessive intermediate a 33.1 MFN2 HSPB8 GJB1 GDAP1
9 charcot-marie-tooth disease, axonal, type 2b2 33.1 NEFL MPZ MFN2 LRSAM1 KIF1B HSPB8
10 charcot-marie-tooth disease, axonal, type 2t 33.1 SH3TC2 SBF2 LRSAM1 GDAP1 FGD4
11 charcot-marie-tooth disease, dominant intermediate b 33.1 SH3TC2 SBF2 MTMR2 MPZ LITAF GJB1
12 charcot-marie-tooth disease, axonal, type 2l 33.1 NEFL MPZ MFN2 KIF1B HSPB8 HSPB1
13 charcot-marie-tooth disease, dominant intermediate d 33.1 MPZ MFN2 KIF1B GJB1
14 charcot-marie-tooth disease, recessive intermediate d 33.1 LRSAM1 GDAP1
15 charcot-marie-tooth disease, axonal, type 2j 33.1 SH3TC2 SBF2 NEFL MTMR2 MPZ GJB1
16 charcot-marie-tooth disease, type 4b1 33.1 SH3TC2 SBF2 MTMR2 MPZ LITAF GDAP1
17 roussy-levy hereditary areflexic dystasia 33.1 PMP22 MPZ
18 charcot-marie-tooth disease, axonal, type 2r 33.1 LRSAM1 GDAP1
19 charcot-marie-tooth disease, dominant intermediate e 33.0 SH3TC2 SBF2 MPZ GDAP1 FGD4
20 charcot-marie-tooth disease, axonal, type 2h 33.0 LRSAM1 GDAP1
21 charcot-marie-tooth disease, dominant intermediate f 33.0 MPZ GDAP1
22 charcot-marie-tooth disease, axonal, type 2i 33.0 SH3TC2 NEFL MPZ MFN2 KIF1B HSPB8
23 neuropathy, hereditary motor and sensory, russe type 33.0 SH3TC2 SBF2 NDRG1 MTMR2 GDAP1 FIG4
24 charcot-marie-tooth disease, axonal, type 2f 33.0 NEFL MTMR2 MPZ MFN2 LITAF KIF1B
25 charcot-marie-tooth disease, x-linked recessive, 2 33.0 PRPS1 MPZ LITAF GJB1 EGR2
26 charcot-marie-tooth disease, x-linked dominant, 1 33.0 SH3TC2 PMP22 NEFL MTMR2 MPZ MFN2
27 charcot-marie-tooth disease dominant intermediate a 33.0 SH3TC2 MPZ GJB1 GDAP1
28 charcot-marie-tooth disease, type 4j 33.0 SH3TC2 SBF2 MTMR2 MPZ LITAF GJB1
29 hereditary motor and sensory neuropathy, type iic 32.9 SH3TC2 SBF2 NEFL MTMR2 MPZ MFN2
30 hereditary sensory neuropathy 32.9 SH3TC2 MPZ GDAP1
31 charcot-marie-tooth disease, type 4d 32.9 SH3TC2 SBF2 NDRG1 MTMR2 MPZ LITAF
32 charcot-marie-tooth disease, type 4a 32.9 SH3TC2 SBF2 MTMR2 MPZ MFN2 LITAF
33 charcot-marie-tooth disease x-linked recessive 4 32.9 PRPS1 MPZ GJB1
34 charcot-marie-tooth disease, demyelinating, type 1d 32.9 SBF2 PMP22 NEFL NDRG1 MTMR2 MPZ
35 charcot-marie-tooth disease, demyelinating, type 1a 32.9 SH3TC2 SBF2 PMP22 NEFL MTMR2 MPZ
36 charcot-marie-tooth disease, type 4b3 32.9 SH3TC2 SBF2 PMP22 MTMR2 MPZ LITAF
37 charcot-marie-tooth disease, demyelinating, type 4f 32.9 SH3TC2 SBF2 MTMR2 MPZ LITAF GJB1
38 charcot-marie-tooth disease, demyelinating, type 1b 32.9 SH3TC2 SBF2 PMP22 NEFL MTMR2 MPZ
39 charcot-marie-tooth disease, demyelinating, type 1f 32.9 SH3TC2 SBF2 PMP22 NEFL MTMR2 MPZ
40 charcot-marie-tooth disease, demyelinating, type 1c 32.9 SH3TC2 SBF2 PMP22 MTMR2 MPZ LITAF
41 charcot-marie-tooth disease type 1g 32.9 PMP22 MPZ LITAF GJB1
42 charcot-marie-tooth disease, type 4h 32.9 SH3TC2 SBF2 NDRG1 MTMR2 MPZ LITAF
43 charcot-marie-tooth disease, axonal, type 2b 32.9 SH3TC2 SBF2 NEFL MTMR2 MPZ MFN2
44 charcot-marie-tooth disease type 2a2a 32.8 MFN2 LRSAM1 KIF1B GDAP1
45 charcot-marie-tooth disease, type 4b2 32.8 SH3TC2 SBF2 NEFL NDRG1 MTMR2 MPZ
46 charcot-marie-tooth disease type 2a2b 32.8 MTMR2 MPZ MFN2 KIF1B GDAP1
47 neuromyotonia and axonal neuropathy, autosomal recessive 32.8 SH3TC2 MPZ MFN2 GJB1
48 charcot-marie-tooth disease intermediate type 32.8 SH3TC2 SBF2 MTMR2 MPZ MFN2 GJB1
49 charcot-marie-tooth disease, axonal, type 2e 32.8 SH3TC2 SBF2 PMP22 NEFL NDRG1 MTMR2
50 charcot-marie-tooth disease, type 4c 32.7 SH3TC2 SBF2 NEFL NDRG1 MTMR2 MPZ

Graphical network of the top 20 diseases related to Tooth Disease:



Diseases related to Tooth Disease
Sources

Symptoms & Phenotypes for Tooth Disease

About this section

UMLS symptoms related to Tooth Disease:


snoring; halitosis; toothache; poor dentition

GenomeRNAi Phenotypes related to Tooth Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.15 EGR2 FGD4 FIG4 GDAP1 GJB1 HSPB1
2 no effect GR00402-S-2 10.15 EGR2 FIG4 GDAP1 HSPB1 HSPB8 KIF1B
3 Increased gamma-H2AX phosphorylation GR00053-A 9.56 EGR2 GJB1 HSPB1 LMNA MPZ NDRG1

MGI Mouse Phenotypes related to Tooth Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.32 EGR2 FGD4 FIG4 GDAP1 GJB1 HSPB8
2 homeostasis/metabolism MP:0005376 10 EGR2 FGD4 GDAP1 GJB1 HSPB1 HSPB8
3 muscle MP:0005369 9.92 FIG4 HSPB8 KIF1B LMNA MFN2 NDRG1
4 behavior/neurological MP:0005386 9.91 EGR2 FGD4 FIG4 GDAP1 GJB1 HSPB8
5 limbs/digits/tail MP:0005371 9.8 EGR2 FIG4 GDAP1 KIF1B LMNA MTMR2
6 mortality/aging MP:0010768 9.47 EGR2 FIG4 GJB1 HSPB8 KIF1B LMNA
Sources

Drugs & Therapeutics for Tooth Disease

About this section

Drugs for Tooth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
2
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
3
Lipoic acid Approved, Investigational, Nutraceutical Phase 4 1200-22-2 864 6112
4 Folate Phase 4
5 Vitamins Phase 4
6 Vitamin B9 Phase 4
7 Trace Elements Phase 4
8 Vitamin B Complex Phase 4
9 Micronutrients Phase 4
10 Antioxidants Phase 4
11 Protective Agents Phase 4
12 Neurotransmitter Agents Phase 4
13 Alpha-lipoic Acid Phase 4
14 Excitatory Amino Acid Antagonists Phase 4
15 Anesthetics, Intravenous Phase 4
16 Anesthetics, General Phase 4
17 Anesthetics, Dissociative Phase 4
18
Acetylcarnitine Approved, Investigational Phase 2, Phase 3 3040-38-8
19
Caffeine Approved Phase 3 58-08-2 2519
20
Ibuprofen Approved Phase 3 15687-27-1 3672
21
Baclofen Approved Phase 3 1134-47-0 2284
22
Sorbitol Approved, Investigational Phase 3 69-65-8, 50-70-4 453 6251 5780
23
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
24
Ethanol Approved Phase 3 64-17-5 702
25
Ascorbic acid Approved, Nutraceutical Phase 2, Phase 3 50-81-7 54676860 54670067 5785
26
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium Experimental Phase 2, Phase 3 461-06-3
27 Nootropic Agents Phase 2, Phase 3
28 Central Nervous System Stimulants Phase 3
29 Phosphodiesterase Inhibitors Phase 3
30 Analgesics Phase 3
31 Antirheumatic Agents Phase 3
32 Cyclooxygenase Inhibitors Phase 3
33 Anti-Inflammatory Agents, Non-Steroidal Phase 3
34 Analgesics, Non-Narcotic Phase 3
35 Pharmaceutical Solutions Phase 3
36 Cathartics Phase 3
37 Laxatives Phase 3
38 GABA Agonists Phase 3
39 Gastrointestinal Agents Phase 3
40 Narcotic Antagonists Phase 3
41 Narcotics Phase 3
42 Neuroprotective Agents Phase 2, Phase 3
43
Epoetin Alfa Phase 2, Phase 3
44 Hematinics Phase 2, Phase 3
45
Mexiletine Approved, Investigational Phase 2 5370-01-4, 31828-71-4 4178
46
Biotin Approved, Investigational, Nutraceutical Phase 2 58-85-5 253 171548
47
Ubidecarenone Approved, Investigational, Nutraceutical Phase 1, Phase 2 303-98-0 5281915
48 Vitamin B7 Phase 2
49 Ubiquinone Phase 1, Phase 2
50
Ulipristal acetate Phase 2 126784-99-4 13559282 130904

Interventional clinical trials:

(show top 50) (show all 132)
# Name Status NCT ID Phase Drugs
1 Success Rate Evaluation of Miniature Pulpotomy With MTA in Primary Molars Unknown status NCT02286648 Phase 4 Formocresol;Mineral Trioxide Aggregate
2 The Association of Alpha Lipoic Acid to the Median Nerve Decompression in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. Completed NCT01895621 Phase 4
3 Effect of Racemic Ketamine on Pain in Females and Males After Surgical Removal of Third Molars Completed NCT00232492 Phase 4 Placebo males;Ketamine 0,1 mg/kg males;Ketamine 0,3 mg/kg males;Ketamine 0,5 mg/kg males;Placebo females;Ketamine 0,1 mg/kg females;Ketamine 0,3 mg/kg females;Ketamine 0,5 mg/kg females
4 Lidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain Withdrawn NCT02748395 Phase 4 Triamcinolone;Lidocaine
5 A Multicenter Study to Evaluate the Effects on Charcot-Marie-Tooth Neuropathy Type 1A of a Composite Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program. Unknown status NCT01289704 Phase 2, Phase 3
6 A Randomized, Placebo-controlled, Double Masked 120 Subject "Futility Design" Clinical Trial of Ascorbic Acid Treatment of Charcot Marie Tooth Disease Type 1A. Completed NCT00484510 Phase 2, Phase 3 Ascorbic acid (Vitamin C);placebo
7 International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months Completed NCT02579759 Phase 3 PXT3003 dose 1;PXT3003 dose 2;placebo
8 Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome; a Randomized Control Trial. Completed NCT02141035 Phase 2, Phase 3 Acetyl-l-carnitine;placebo
9 Clinical Evaluation of Cemented and Angulated Screw-retained Crowns Following Immediate Implant Placement: a Randomized Controlled Clinical Trials Completed NCT04160247 Phase 3
10 A Single-centre, Double-blind, Randomised, Two-stage, Parallel-group Study to Assess the Efficacy and Safety of the Fixed Dose Combination of Ibuprofen 400 mg and Caffeine 100 mg Versus Ibuprofen 400 mg, Caffeine 100 mg and Placebo in Patients With Postoperative Dental Pain Completed NCT01929031 Phase 3 ibuprofen + caffeine;ibuprofen;caffeine;placebo
11 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A) Treated 15 Months Recruiting NCT05092841 Phase 3 PXT3003;PXT3003 placebo
12 A Randomised, Double-blind, Double-dummy, Parallel-group, Single Dose, Active and Placebo-controlled Efficacy and Pharmacokinetics/Pharmacodynamics Study of 2 x 200 mg Ibuprofen Liquid Capsules for the Treatment of Pain After Surgical Removal of Impacted Third Molars. Recruiting NCT05484401 Phase 3 Ibuprofen 200Mg Oral Cap;Ibuprofen 200Mg Oral Tablet
13 International, Multi-center, Open Label, Follow-up Extension Study Assessing the Long-term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Active, not recruiting NCT03023540 Phase 3 PXT3003
14 A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A) Active, not recruiting NCT04762758 Phase 3 (RS)-baclofen, naltrexone hydrochloride and D-sorbitol;Placebo
15 Recombinant Human Erythropoietin (r-HuEPO) in the Prevention of Neurologic Sequelae From Malignant Spinal Cord Compression: a Multi-Center, Placebo-Controlled, Phase 2 Randomized Study Terminated NCT00220675 Phase 2, Phase 3 Erythropoietin infusion
16 The Influence of Pronator Teres Release in the Treatment of Median Nerve Compression Neuropathy: A Randomized Prospective Study Unknown status NCT01562860 Phase 2
17 SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Completed NCT02967679 Phase 2 MD1003
18 Effects of Coenzyme Q10 (CoQ10) on Subjects With Charcot-Marie-Tooth Disease (CMT):A Double Blind, Randomized, Controlled Trial With an Open Label Follow-up Study Completed NCT00541164 Phase 1, Phase 2 Coenzyme Q10
19 Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease Completed NCT02561702 Phase 2 Mexiletine
20 A Phase II, Randomized, Placebo-controlled Trial of the Safety, Efficacy, Pharmacodynamics and Pharmacokinetics of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A. Completed NCT01401257 Phase 2 PXT3003 Low dose;PXT3003 Intermediate Dose;PXT3003 High Dose
21 Single Center, Open Label, Repeat Intramuscular Administration, 270 Days, Phase I/2a Clinical Trial to Evaluate Safety, Tolerability of Investigational Product (Engensis: VM202) With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A) Completed NCT05361031 Phase 1, Phase 2
22 Phase 2 Study of Ascorbic Acid Treatment in Charcot-Marie-Tooth Type 1A Completed NCT00271635 Phase 2 Placebo;ascorbic acid
23 Neuropathy Along the Median Nerve: Etiology of Symptoms Associated With the Carpal Tunnel Syndrome, a Preliminary Study Completed NCT00634738 Phase 1, Phase 2
24 Phase I/IIa Trial Evaluating scAAV1.tMCK.NTF3 for Treatment of Charcot-Marie-Tooth Neuropathy Type 1A (CMT1A) Suspended NCT03520751 Phase 1, Phase 2 scAAV1.tMCK.NTF3
25 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X Terminated NCT03124459 Phase 2 ACE-083;Placebo
26 A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Charcot-Marie-Tooth Disease Terminated NCT03254199 Phase 2 FLX-787-ODT (orally disintegrating tablet);Placebo ODT
27 An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) Previously Enrolled in Study A083-02 and in Patients With Charcot-Marie Tooth (CMT) Disease Types 1 and X Previously Enrolled in Study A083-03 Terminated NCT03943290 Phase 2 ACE-083
28 LONG-TERM EFFECTS TOLERANCE AND THE Ulipristal Acetate IN DISEASE Charcot-MARIE-TOOTH TYPE OF 1A Terminated NCT02600286 Phase 2 EllaOne;EllaOne placebo
29 Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A Recruiting NCT05333406 Phase 1 EN001
30 Muscle MRI in Charcot Mary Tooth Disease: a Prospective Cohort Study Unknown status NCT03550300
31 Development of the Charcot-Marie-Tooth Disease Infant Scale (CMTInfS) for Infants With CMT Unknown status NCT02979145
32 Evaluation of the Analgesic Efficiency of the Transcutaneous Neurostimulation in the Charcot Syndrome Marie Tooth on the Pains of Lower Limbs Unknown status NCT01918826
33 The Feasibility and Effect of Ankle Foot Orthoses and Underfoot Vibration on the Postural Stability of People With Inherited Neuropathy Unknown status NCT03278093
34 Clinical Comparison of Bulk-fill and Incremental Composite Resin Restorations Unknown status NCT04685954
35 Quantification of Nerve Stiffness in Patients With Peripheral Neuropathies Unknown status NCT03397303
36 Clinical Evaluation of Two Low-shrinkage Composites After Different Preparation Techniques Unknown status NCT03708510
37 Clinical Efficacy of Ceramic vs Resin Bloc Endocrowns: Study Protocol for the Randomized Clinical Trial Unknown status NCT04033380
38 Clinical Trial of Safety and Efficacy of the Medical Item Collagen Plates With Hydroxyapol Inducing Angiogenesis, "Nukleostim", for Bone Tissue Regeneration Unknown status NCT02293031
39 Linkage and Identification of (a) Candidate Gene(s) for Tooth Disorders Unknown status NCT00026026
40 BALTiC Study: A Feasibility Analysis of Home Based BALance Training in People With Charcot-Marie-Tooth Disease Completed NCT02982343
41 Survey of Current Management of Orthopaedic Complications in Charcot Marie Tooth Disease Patients Completed NCT02001038
42 Development and Validation of a Disability Severity Index for Charcot Marie Tooth Disease Completed NCT01455623
43 Correlation Between Clinical and Electrophysiological Phenotypes in a Population of Patients With Neuropathy Charcot-Marie-Tooth Disease Type 1A Completed NCT01750710
44 A Randomized Double Blind Longitudinal Study to Determine Motor Unit Number Index Variability in CMT1A Patients Undergoing a Home Ankle Strengthening Program Versus Standard of Care Completed NCT03715283
45 A Prospective, Multicenter, Randomized Multicenter Study of Short Implants Used to Obviate the Need for Sinus Augmentation: an Assessment of Clinical Outcomes and Resource Allocation. Completed NCT00725049
46 A Prospective, Observational Study of Osseotite Certain IOL (Immediate Occlusal Loading) Implants in Immediate Occlusal Loading of Short Span Fixed Restorations Completed NCT00728962
47 A Prospective, Randomized-Controlled, Multicenter Study of NanoTite Implants Placed Into Fresh Sinus Lift Augmentation Sites Completed NCT00713206
48 Patient Reported Outcomes Measures (PROM) in Carpal Tunnel Therapies in Patients With Inherited Neuropathies Completed NCT02788734
49 A Prospective Randomized-controlled Evaluation of Nanotite and Osseotite Surfaced Implant Performance in Graduate Student Programs Completed NCT00726063
50 Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Completed NCT02011204

Search NIH Clinical Center for Tooth Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Camphor
CAMPHOR CRYSTALS
CAMPHOR GUM
CAMPHOR,MONOBROMATED

Cochrane evidence based reviews: tooth diseases

Sources

Genetic Tests for Tooth Disease

About this section
Sources

Anatomical Context for Tooth Disease

About this section

Organs/tissues related to Tooth Disease:

FMA: Teeth
MalaCards : Spinal Cord, Bone, Tonsil, Skeletal Muscle, Dorsal Root Ganglion, Brain, Skin
Sources

Publications for Tooth Disease

About this section

Articles related to Tooth Disease:

(show top 50) (show all 3477)
# Title Authors PMID Year
1
Mutation analysis in patients with nonsyndromic tooth agenesis using exome sequencing. 41
36017684 2022
2
Developmental Abnormalities of Teeth in Children With Nephrotic Syndrome. 41
35277264 2022
3
Medical Conditions, Oral Health Practices, and Barriers to Treatment among Patients Visiting a Teaching Dental Hospital in Eastern Saudi Arabia. 41
35153627 2022
4
A SARM1-mitochondrial feedback loop drives neuropathogenesis in a Charcot-Marie-Tooth disease type 2A rat model. 62
36287202 2022
5
Evidence of nerve hypertrophy in patients with inclusion body myositis on lower limb MRI. 62
36151728 2022
6
TFG mutation induces haploinsufficiency and drives axonal Charcot-Marie-Tooth disease by causing neurite degeneration. 62
35986567 2022
7
Autophagic lysosome reformation in health and disease. 62
36409033 2022
8
Precision mouse models of Yars/dominant intermediate Charcot-Marie-Tooth disease type C and Sptlc1/hereditary sensory and autonomic neuropathy type 1. 62
34875719 2022
9
A novel splicing mutation in 5'UTR of GJB1 causes X-linked Charcot-Marie-tooth disease. 62
36394156 2022
10
Beware next-generation sequencing gene panels as the first-line genetic test in Charcot-Marie-Tooth disease. 62
36376020 2022
11
Frequency, entity and determinants of fatigue in Charcot-Marie-Tooth disease. 62
36458502 2022
12
EGR2-related mixed demyelinating and axonal Charcot-Marie-Tooth disease: An electrodiagnostic, nerve imaging, and histological study. 62
35770518 2022
13
Young infants with PMP22 duplication can have minor nerve conduction study abnormalities. 62
36253232 2022
14
NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice. 62
35148379 2022
15
A new mouse model of Charcot-Marie-Tooth 2J neuropathy replicates human axonopathy and suggest alteration in axo-glia communication. 62
36350884 2022
16
No Association between the SORD Gene and Amyotrophic Lateral Sclerosis in a Chinese Cohort. 62
36431311 2022
17
A method to identify, dissect and stain equine neuromuscular junctions for morphological analysis. 62
36087283 2022
18
The 2022 Lady Estelle Wolfson lectureship on neurofilaments. 62
35950263 2022
19
Clinically relevant mouse models of Charcot-Marie-Tooth Type 2S. 62
36413117 2022
20
Knock-in mouse models for CMTX1 show a loss of function phenotype in the peripheral nervous system. 62
36403785 2022
21
Identification of a rare missense mutation in GJB1 and prenatal diagnosis in a Chinese family with CMT: A case report. 62
36397455 2022
22
Dynamin-2 deficiency causes age- and sex-dependent neutropenia and myelodysplasia in mice. 62
36417761 2022
23
Chloroquine corrects enlarged lysosomes in FIG4 null cells and reduces neurodegeneration in Fig4 null mice. 62
36434903 2022
24
A missense, loss-of-function YARS1 variant in a patient with proximal-predominant motor neuropathy. 62
36307205 2022
25
Biallelic variants in WARS1 cause a highly variable neurodevelopmental syndrome and implicate a critical exon for normal auditory function. 62
35815345 2022
26
Virtual Charcot-Marie-Tooth Examination Score: A Validated Virtual Evaluation for People With Charcot-Marie-Tooth Disease. 62
36380896 2022
27
Magnetic resonance imaging-based lower limb muscle evaluation in Charcot-Marie-Tooth disease type 1A patients and its correlation with clinical data. 62
36198750 2022
28
Blood biomarkers of peripheral neuropathy. 62
35611606 2022
29
Stance and swing phase ankle phenotypes in youth with Charcot-Marie-Tooth type 1: An evaluation using comprehensive gait analysis techniques. 62
36179412 2022
30
Screening for SH3TC2 variants in Charcot-Marie-Tooth disease in a cohort of Chinese patients. 62
33587240 2022
31
Disease Progression in Charcot-Marie-Tooth Disease Related to MPZ Mutations: A Longitudinal Study. 62
36203352 2022
32
Mutations in MYO9B are associated with Charcot-Marie-Tooth disease type 2 neuropathies and isolated optic atrophy. 62
36260368 2022
33
Imbalance of NRG1-ERBB2/3 signalling underlies altered myelination in Charcot-Marie-Tooth disease 4H. 62
36314052 2022
34
Hereditary motor and sensory neuropathy with SOD1-mutant: A case report. 62
36316849 2022
35
HINT1 neuropathy in Lithuania: clinical, genetic, and functional profiling. 62
36242072 2022
36
WARS1 and SARS1: Two tRNA synthetases implicated in autosomal recessive microcephaly. 62
35790048 2022
37
Heterozygous Seryl-tRNA Synthetase 1 Variants Cause Charcot-Marie-Tooth Disease. 62
36088542 2022
38
Hereditary motor and sensory neuropathy type VIA with optic nerve pallor in two sisters with pathologic myopia: a case series and review. 62
36098092 2022
39
Histidine supplementation can escalate or rescue HARS deficiency in a Charcot Marie Tooth Disease model. 62
36164730 2022
40
Management of Stress Urinary Incontinence With Pelvic Floor Muscle Training for a Woman With Charcot-Marie-Tooth Disease: A Case Report. 62
36118110 2022
41
Anaesthesia management of a child with Charcot-Marie-Tooth disease for orthopaedic surgery. 62
36388447 2022
42
Anxiety and depression in Charcot-Marie-Tooth disease: data from the Italian CMT national registry. 62
36114297 2022
43
Genotype-phenotype characteristics of Vietnamese patients diagnosed with Charcot-Marie-Tooth disease. 62
35938991 2022
44
Patient-Reported Symptom Burden of Charcot-Marie-Tooth Disease Type 1A: Findings From an Observational Digital Lifestyle Study. 62
36005469 2022
45
Connexins and Pannexins: Important Players in Neurodevelopment, Neurological Diseases, and Potential Therapeutics. 62
36140338 2022
46
Deep vein thrombosis and acute hepatitis after ChAdOx1 nCov-19 vaccination in a Charcot-Marie-Tooth patient: a case report. 62
36451672 2022
47
Heterogeneous Clinical Phenotypes of dHMN Caused by Mutation in HSPB1 Gene: A Case Series. 62
36291591 2022
48
Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutations. 62
36090755 2022
49
Partial loss-of-function variant in neuregulin 1 identified in family with heritable peripheral neuropathy. 62
35485770 2022
50
Clinical and genetic characterization of NEFL-related neuropathy in Taiwan. 62
36031490 2022
Sources

Variations for Tooth Disease

About this section
Sources

Expression for Tooth Disease

About this section
Search GEO for disease gene expression data for Tooth Disease.
Sources

Pathways for Tooth Disease

About this section

Pathways related to Tooth Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neural crest differentiation 74
11.34 PMP22 MPZ GJB1
2
Intracellular trafficking proteins involved in CMT neuropathy 74
10.98 SH3TC2 SBF2 PMP22 NEFL NDRG1 MTMR2
3
EGR2 and SOX10-mediated initiation of Schwann cell myelination 66
10.58 PMP22 MPZ EGR2
Sources

GO Terms for Tooth Disease

About this section

Cellular components related to Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon cytoplasm GO:1904115 9.1 NEFL KIF1B HSPB1

Biological processes related to Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of myelination GO:0031642 9.56 MTMR2 FIG4
2 peripheral nervous system myelin maintenance GO:0032287 9.46 SH3TC2 NDRG1
3 myelin assembly GO:0032288 9.43 PMP22 MTMR2 FIG4
4 myelination GO:0042552 9.28 SBF2 PMP22 MTMR2 MPZ FIG4 EGR2

Molecular functions related to Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.55 SBF2 PRPS1 NEFL MTMR2 LMNA LITAF
Sources

Sources for Tooth Disease

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....